NRG-GY032
Open to Accrual
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
A Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-Wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER)
Principal Investigator
Status
Open to Accrual
Temporarily Closed to Accrual
April 16, 2024
Open to Accrual
June 24, 2024
Disease Site
Gynecologic [GY] Uterine Corpus
Phase
II
Developmental Therapeutics
No
Primary Objective
Estimate the rate of pelvic recurrence at 3 years in patients who are treated with a de-escalated adjuvant treatment directed by tumour molecular status.
Patient Population
NRG-GY032: Patients with POLE-mutated or p53wt/NSMP early-stage endometrial cancer (EC).
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
